First New Treatment in a Decade for ANCA-Vasculitis Approved
October 8, 2021Dextenza Approved to Treat Itching in the Eye Caused by Allergies
October 11, 2021October 11, 2021 – Rethymic® (allogenic processed thymus tissue-agdc) has been approved as a one-time treatment for congenital athymia in pediatric patients.
- Congenital athymia is a rare immune disorder that occurs when a person is born without a thymus gland. This gland is critical to proper function of the immune system. Children born without it may suffer from frequent life-threatening infections and often do not survive beyond two years of age.
- Rethymic is the first treatment of its kind to be approved by the U.S. FDA. It consists of donor- derived, lab-cultured thymus tissue used to improve immune function.
- Manufactured by Enzyvant, Rethymic is administered via a surgical implantation. The dose is calculated at the manufacturing facility, and the amount of Rethymic provided for the procedure is customized to the specific patient.
- Rethymic has a wholesale acquisition cost (WAC) of $2,729,500 per implant.